ReviewThe meaning of hypokalemia in heart failure
Section snippets
Epidemiology of hypokalemia in heart failure (HF)
Congestive heart failure carries a grim prognosis. The 5-year survival rate is well below 40% [1], with half of the deaths classified as sudden [2], [3]. These deaths were probably caused by ventricular arrhythmias or electromechanical dissociation [4], [5], [6]. Electrophysiological remodeling is associated with the progression of hypertrophy and heart failure (HF) [7].
Potassium (K+) is an important electrolyte essential for a healthy nervous system and a regular heart rhythm [7], [8]. K+
Etiology and pathophysiology of hypokalemia in HF
The sodium-rich diet of modern humans may produce sodium overload and K+ depletion [10]. Hypokalemia contributes to the pathogenesis of cardiovascular disease, and many cardiovascular disorders and drugs cause hypokalemia [11], [12].
Patients with HF may have difficulty with K+ transport into tissues. In patients with HF, an increase in oxidative stress may result in a defect in Na+/K+-ATPase activity and thus in transport of K+ into tissues. Consequently, tissue levels of K+ may be considerably
Effect of hypokalemia in HF
Hypokalemia causes cellular hyperpolarity, increases resting potential, hastens depolarization, and increases automaticity and excitability [31], [32]. Because cardiac repolarization relies on K+ influx, hypokalemia lengthens the action potential and increases QT dispersion reflecting electrical inhomogeneity. Most patients with HF have increased ventricular ectopy, and 50% exhibit nonsustained ventricular tachycardia [33]. A total of 50% of deaths from HF are sudden, presumably due to
Prevention and treatment of hypokalemia in HF
The combination drug therapy may simultaneously improve clinical outcomes while it enhances the risk of K+-related adverse events [47]. The K+-sparing diuretics are important in preventing hypokalemia in HF [47].
The K+-sparing diuretics include spironolactone and eplerenone. Unlike loop and thiazide diuretics, these drugs do not act directly on sodium transport. Some drugs in this class antagonize the actions of aldosterone (aldosterone receptor antagonists) at the distal segment of the distal
Potassium supplements in HF patients
K+ supplements are commonly used to treat hypokalemia and maintain normokalemia. However, their long-term effects on outcomes in chronic heart failure are unknown. Ekundayo et al. used a public-use copy of the Digitalis Investigation Group (DIG) trial dataset to determine the association of K+ supplement use with outcomes with a propensity-matched design. Although the use of K+ supplements in chronic heart failure was not associated with mortality (HR when K+ supplement use was compared with
Conclusions
Hypokalemia is common in HF patients, often due to a defect in Na+/K+-ATPase activity and intracellular shift of K caused by oxidative stress and neurohormonal activation. Serum K+ levels have important therapeutic and prognostic implication for HF patients. While diuretics, commonly used in HF may cause hypokalemia, neurohormonal blockade using ACE inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists may cause hyperkalemia. Hypokalemia is associated with
Declaration of interest
The authors have not received any payments in connection with the preparation of this review. No pharmaceutical company supported or was involved with the preparation of this article.
Acknowledgement
The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology [62].
References (62)
- et al.
What is the optimal serum potassium level in cardiovascular patients?
J Am Coll Cardiol
(2004) - et al.
High sodium-low potassium environment and hypertension
Am J Cardiol
(1976) - et al.
What is the optimal serum potassium level in cardiovascular patients?
J Am Coll Cardiol
(2004) - et al.
Hypertension and cardiac failure in its various forms
Med Clin North Am
(2009) - et al.
Effect of long-term diuretic treatment on body-potassium in heart-disease
Lancet
(1976) - et al.
Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias
Prog Cardiovasc Dis
(1966) - et al.
Frequency of hypokalemia after successfully resuscitated out-of hospital cardiac arrest compared with that in transmural acute myocardial infarction
Am J Cardiol
(1987) - et al.
What is the optimal serum potassium level in cardiovascular patients?
J Am Coll Cardiol
(2004) - et al.
Impairment of cardiac function by moderate potassium depletion
J Card Fail
(1995) - et al.
A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure
Int J Cardiol
(2009)
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial
Int J Cardiol
Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia
Am Heart J
Drug-induced hyperkalemia: old culprits and new offenders
Am J Med
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases
Am J Med
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
J Card Fail
Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure
J Card Fail
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study
Int J Cardiol
Ethics in the authorship and publishing of scientific articles
Int J Cardiol
Changing epidemiological features of cardiac failure
Br Heart J
Effects of vasodilator therapy on mortality in chronic congestive heart failure: a result of a veterans affairs comparative study (V-HEFT)
New Engl J Med
A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure
New Engl J Med
Cardiac arrest recorded on ambulatory electrocardiograms
Am J Cardiol
Diverse mechanisms of unexpected cardiac arrest in advanced heart failure
Circulation
Sudden death prevention in patients with advanced ventricular dysfunction
Circulation
Electrophysiological remodeling in hypertrophy and heart failure
Cardiovasc Res
Difficulties in maintaining potassium homeostasis in patients with heart failure
Clin Cardiol
Hypokalemia and cardiovascular disease
Am J Cardiol
Do non-potassium sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence
Drugs
Changes in plasma ionized calcium and RBC K content in severe hyperkalemia: new electrocardiographic concept
Circulation
New guidelines for potassium replacement in clinical practice. A contemporary review by the National Council on Potassium in Clinical Practice
Arch Intern Med
Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension
Br Heart J
Cited by (59)
Consequences of COVID-19 on the cardiovascular and renal systems
2022, Sleep MedicineCitation Excerpt :One cohort study [99] of 175 patients of COVID-19 reported that 55% patients developed hypokalemia (18% with severe hypokalemia), whereas the proportion of hypokalemia among critically ill patients reached 85%. The authors also mentioned that hypokalemia might be associated with enhanced potassium excretion, which was secondary to activation of the RAAS, caused by the reduction in ACE2 activity [99,134]. However, other researchers believed that hypokalemia might also be secondary to diarrhea induced by SARS-CoV-2, the use of diuretics or other drugs, and cannot be simply explained by activation of the RAAS, at least more evidence should be presented [135].
Essential metals in health and disease
2022, Chemico-Biological InteractionsCitation Excerpt :Renal loss of potassium is a rather complex problem and may occur from the adverse effect of anticancer therapy (cis-platin) or use of antibiotics (gentamicin, penicillin) or diuretics. Hypokalemia occurs among patients with congestive heart failure as a result of altered of Na,K-pump activity, with an oxidative stress-modified distribution of potassium and neurohormonal activation [40]. Heart failure is known to stimulate metabolic changes such as insulin resistance, which may exacerbate the initial condition [41].
Persistent Hypokalemia post SARS-coV-2 infection, is it a life-long complication? Case report
2021, Annals of Medicine and SurgeryHypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients
2020, International Journal of Infectious DiseasesCitation Excerpt :The role of gastrointestinal symptoms in the development of hypokalemia is not supported by the present study results, in accordance with cohort data from China (Chen et al., 2020a). Aside from being a marker of severity, the clinical relevance of hypokalemia in this clinical setting lies in the fact that it would potentially contribute to myocardial dysfunction, ventricular arrhythmia (Bielecka-Dabrowa et al., 2012), and respiratory muscle dysfunction. Nonetheless, the impact of hypokalemia on myocardial and respiratory function in COVID-19 patients is not clear, and direct evidence demonstrating that SARS-CoV-2 infects the human heart and decreases ACE2 expression is currently lacking.
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review
2020, Journal of the American College of CardiologyEvaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure
2020, Nutrition, Metabolism and Cardiovascular DiseasesCitation Excerpt :Some aspects of our study warrant discussion. Patients were stratified based on LD usage and spironolactone usage primarily because these medications are known to directly increase the risk of hypo and hyper-kalemia within this population [24,25]. Nevertheless, other medical therapies such as angiotensin receptor blockers, angiotensin-converting enzyme inhibitors and B-blockers are also known to cause disturbances in potassium balance [45].